The Cambridge, England-based pharmaceutical company said its Kalos and Logos phase 3 trials showed Breztri achieved statistically significant and clinically meaningful improvements in lung function ...

AstraZeneca announced on Friday that its inhaled triple-combination therapy ‘Breztri Aerosphere’ met all primary endpoints in ...

AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for ...

Anglo-Swedish drugmaker AstraZeneca on Friday said its inhaler therapy Breztri Aerosphere met all the main goals of two ...

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some ...

Curating today’s top interviews from around Bloomberg News. Hear conversations with the biggest names in finance, politics ...

AstraZeneca CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

London: British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said ...

The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the U.S.